Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.